Could proposed legislation undercut the promise of targeted therapies?
Jim Hollingshead, Deloitte Consulting LLP
Advertisement
Articles by Jim Hollingshead, Deloitte Consulting LLP
Advertisement
Latest Updated Articles
- The stakes are high in the debate over follow-on biologics
Published: May 3rd 2009 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
It’s Official: CMS Unveils Big Price Cuts for 15 High-Cost Medicare Drugs in Latest IRA Negotiation Round
2
What Sets True DSCSA Readiness Apart?
3
Medicare Set to Unveil Prices for 15 High-Cost Drugs
4
Pharma Pulse: Medicare Price Negotiations Heat Up, as FDA Approves SMA Gene Therapy
5
